Nkarta Inc (NKTX NASDAQ) stock market data APIs
$3.0457
-0.1(-3.3%)
as of May 4, 2026
Try our APIs with
free plan!
Nkarta Inc Financial Data Overview
Price chart is built with
Anychart
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Prev. Close
3.0457
Open
2.9441
High
3.1063
Low
2.876
52 wk Range
1.63-3.65
Market Cap
215 M
Shares Outstanding
71 291 K
Revenue
385
EPS
-0.37
Beta
0.887
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nkarta Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nkarta Inc data using free add-ons & libraries
Get Nkarta Inc Fundamental Data
Nkarta Inc Fundamental data includes:
- Net Revenue: 385
- EBITDA: -106 645 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-26
- EPS/Forecast: -0.295
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nkarta Inc News
New
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program
Nkarta NKTX shares surged 15.7% on Thursday, reflecting strong investor optimism following a meaningful regulatory update tied to its lead autoimmune program, NKX019, an investigational CAR-NK cell th...
Nkarta files $350M shelf offering, plans $100M ATM stock sale via Stifel
* Nkarta (NKTX [https://seekingalpha.com/symbol/NKTX]) filed a $350M mixed-securities shelf offering with the SEC [https://seekingalpha.com/filing/222268734] to raise funds and plans to sell up to $...
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight
The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD, SL...
Nkarta to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to tre...
Get Nkarta Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
